Description

Kratos Stack (LGD-4033 + MK-2866) – Product Details

The Kratos Stack consists of two selective androgen receptor modulators (SARMs): LGD-4033 (Ligandrol) and MK-2866 (Ostarine). When considering the Kratos Stack, the idea behind combining LGD-4033 and MK-2866 could be to potentially achieve synergistic effects in terms of muscle growth, strength enhancement, and body composition improvement. However, it is important to note that the specific effects of combining these two compounds have not been extensively studied, and their safety and potential risks in combination are not well-understood.

To gain a better understanding of the effects and interactions of the Kratos Stack, it would be necessary to consult scientific literature, preclinical research, and studies conducted on cell cultures or animal models.

• Kratos consists of  LGD-4033 and Ostarine.
• Capsules consist of 25mg LGD 4033 and 25mg Ostarine, totaling 50mg per capsule and 2000mg in total.
• The liquid is offered as 33.3mg LGD-4033, and 33.3mg Ostarine, totaling 67mg per ml for 30ml, or 2000mg in total.

LGD-4033

Ligandrol is a novel nonsteroidal oral selective androgen receptor modulator currently being investigated in research as a potential treatment for conditions relating to muscle dystrophy and osteoporosis.

Recent studies investigated the effects of LGD 4033 on muscle tissue in ovariectomized rats. A daily dose of LGD was administered and calculated according to the body weight of each individual rat at the onset of the study. Results and changes were noted as soon as week 2, the control group having weighed significantly less than rats undergoing LGD treatment. This difference remained until the end of the study, irrespective of LGD treatments. Additionally, the LGD treatments resulted in a higher number of capillaries in all muscles studied. Longer randomized trials and research could potentially evaluate its efficacy in improving physical function and health outcomes in select populations.

Ostarine (MK-2866)

Ostarine, also known as MK-2866, is currently one of the best research compounds focused on cutting. Initially, however, Ostarine was created to help fight muscle-wasting diseases. According to research, it selectively binds to androgen receptors in the body and displayed beneficial effects on muscle structure and metabolism in ovariectomized rats. Ostarine also displayed improved muscle vascularization in ovariectomized rats. This yields massive potential in the field of research to further investigate the possibility of preserving lean muscle tissue during a caloric deficit.